Key facts
- Exciva’s last known valuation is $16.4M (Oct 2021).
- It has raised $70.1M; the latest was Later Stage VC ($59.7M) in Jan 2026.
- Notable investors include EQT Life Sciences, Modi Ventures, Andera Partners, LBBW Venture Capital, LifeArc — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Exciva
- ·The full record, as it builds
Funding rounds
No funding rounds for Exciva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exciva
Developer of antitussive medication designed to address both the neurological and psychological aspects of behavioral and psychological symptoms. The company specializes in developing disease-modifying therapies, cures, prophylactics, supplements, formulations, and methods for making and using such compositions, enabling the healthcare industry to access its program for rescuing and repurposing approved drugs for new indications and uses.
- Sector
- Healthcare
- HQ
- Heidelberg, Germany
- Founded
- 2015
- Employees
- 5
- Website
- exciva.com/
- Ownership
- Privately Held (backing)
Exciva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exciva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exciva in its N-PORT filings yet. We sweep new filings monthly.